 Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of 13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately 125.1 million. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions. 